May 09, 2025 / 03:30AM GMT
Kiran Shaw - Biocon Ltd - Executive Chairperson of the Board
(technical difficulty) Steady progress in Biosimilars and ongoing traction in Research Services.
Moving to discuss the financial highlights. For Q4, revenue from operations reached INR4,417 crore, reflecting a solid 15% year-on-year increase on a like-for-like basis and a 16% sequential growth. This growth was driven by a 46% year-on-year growth for Generics, 9% for Biosimilars and 11% for Research Services. Sequentially, all segments reported growth. Generics, particularly, was up 53%, while both Biosimilars and Research Services were up 8%.
Core EBITDA for the quarter stood at INR1,363 crore, a 16% increase from last year with a healthy core operating margin of 31%. R&D investment for the quarter was INR231 crore, accounting for 7% of revenues with, of course, excluding Syngene. Reported EBITDA for Q4 was INR1,150 crore, which is a 60% year-on-year growth on a like-for-like basis. Profit before tax, excluding exceptional items, was INR466 crore, a strong 45% increase on a like-for-like basis.
Now moving to full
Full Year 2025 Biocon Ltd Earnings Call Transcript
May 09, 2025
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers